EE200200217A - Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod - Google Patents

Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod

Info

Publication number: EE200200217A
Authority: EE; Estonia
Prior art keywords: preparation; modulation; drug; substituted indoles; nfkb activity
Prior art date: 1999-10-26

Application number

EEP200200217A

Other languages

English (en)

Inventor

Ritzeler Olaf

Ulrich Stilz Hans

Neises Bernhard

Jaehne Gerhard

Habermann J�rg

Original Assignee

Aventis Pharma Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-26

Filing date

2000-10-17

Publication date

2003-06-16

2000-10-17 Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh

2003-06-16 Publication of EE200200217A publication Critical patent/EE200200217A/et

2008-06-16 Publication of EE05036B1 publication Critical patent/EE05036B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)

EEP200200217A 1999-10-26 2000-10-17 Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod EE05036B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19951360A DE19951360A1 (de)	1999-10-26	1999-10-26	Substituierte Indole
PCT/EP2000/010210 WO2001030774A1 (de)	1999-10-26	2000-10-17	Substituierte indole zur modulierung von nfkb-aktivität

Publications (2)

Publication Number	Publication Date
EE200200217A true EE200200217A (et)	2003-06-16
EE05036B1 EE05036B1 (et)	2008-06-16

Family

ID=7926798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200217A EE05036B1 (et)	1999-10-26	2000-10-17	Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod

Country Status (31)

Country	Link
US (3)	US20030119820A1 (et)
EP (1)	EP1261601B1 (et)
JP (1)	JP3843012B2 (et)
KR (1)	KR100795709B1 (et)
CN (1)	CN1172929C (et)
AT (1)	ATE437867T1 (et)
AU (1)	AU781553B2 (et)
BR (1)	BR0015026B1 (et)
CA (1)	CA2389165C (et)
CY (1)	CY1110521T1 (et)
CZ (1)	CZ304885B6 (et)
DE (2)	DE19951360A1 (et)
DK (1)	DK1261601T3 (et)
EE (1)	EE05036B1 (et)
ES (1)	ES2329871T3 (et)
HR (1)	HRP20020357B1 (et)
HU (1)	HU229215B1 (et)
IL (2)	IL149272A0 (et)
ME (1)	ME00434B (et)
MX (1)	MXPA02003998A (et)
NO (1)	NO323952B1 (et)
NZ (1)	NZ518587A (et)
PL (1)	PL200115B1 (et)
PT (1)	PT1261601E (et)
RS (1)	RS50424B (et)
RU (1)	RU2255087C2 (et)
SI (1)	SI1261601T1 (et)
SK (1)	SK287116B6 (et)
TR (1)	TR200201144T2 (et)
WO (1)	WO2001030774A1 (et)
ZA (1)	ZA200203204B (et)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK288019B6 (sk)	1999-12-24	2012-11-05	Aventis Pharma Limited	Azaindoles derivatives, their use and pharmaceutical composition containing thereof
EA200300508A1 (ru)	2000-10-26	2004-06-24	Туларик Инк.	Противовоспалительные агенты
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
EP2335700A1 (en) *	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
AU2002319814A1 (en) *	2001-08-13	2003-03-03	E.I. Du Pont De Nemours And Company	Substituted 1h-dihydropyrazoles, their preparation and use
JP4599501B2 (ja)	2001-11-07	2010-12-15	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体
AU2002365611A1 (en)	2001-12-05	2003-06-17	F. Hoffmann - La Roche Ag	Inflammation modulators
ES2262996T3 (es)	2002-01-07	2006-12-01	Eisai Co., Ltd.	Deazapurinas y sus usos.
PL373424A1 (en)	2002-06-06	2005-08-22	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US6974870B2 (en)	2002-06-06	2005-12-13	Boehringer Ingelheim Phamaceuticals, Inc.	Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
AU2003270701B2 (en)	2002-10-31	2009-11-12	Amgen Inc.	Antiinflammation agents
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7098231B2 (en)	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP1462105A1 (en) *	2003-03-28	2004-09-29	Procorde GmbH	Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases
HRP20050926A2 (en) *	2003-04-09	2006-06-30	Millennium Pharmaceuticals	Beta-carbolines useful for treating inflammatory disease
US20050004164A1 (en) *	2003-04-30	2005-01-06	Caggiano Thomas J.	2-Cyanopropanoic acid amide and ester derivatives and methods of their use
CN103319464A (zh)	2004-02-20	2013-09-25	贝林格尔.英格海姆国际有限公司	病毒聚合酶抑制剂
TW200539880A (en)	2004-04-09	2005-12-16	Millennium Pharm Inc	Beta-carbolines useful for treating inflammatory disease
TWI391387B (zh) *	2004-05-12	2013-04-01	Eisai R&D Man Co Ltd	具有哌啶環之吲哚衍生物
US7425580B2 (en)	2004-05-19	2008-09-16	Wyeth	(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
TW200616967A (en)	2004-06-24	2006-06-01	Smithkline Beecham Corp	Novel indazole carboxamides and their use
PE20060748A1 (es)	2004-09-21	2006-10-01	Smithkline Beecham Corp	Derivados de indolcarboxamida como inhibidores de quinasa ikk2
DE102005025225A1 (de)	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
EA014083B1 (ru)	2005-06-30	2010-08-30	Смитклайн Бичам Корпорейшн	Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
EP1915378A4 (en)	2005-08-12	2009-07-22	Boehringer Ingelheim Int	VIRUS POLYMERASE INHIBITORS
JP2009001495A (ja) *	2005-10-13	2009-01-08	Taisho Pharmaceutical Co Ltd	２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
UA95788C2 (en) *	2005-12-15	2011-09-12	Ф. Хоффманн-Ля Рош Аг	Fused pyrrole derivatives
WO2007146602A1 (en)	2006-06-06	2007-12-21	Boehringer Ingelheim International Gmbh	Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
KR20090047458A (ko)	2006-08-08	2009-05-12	사노피-아벤티스	아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
CA2674865A1 (en) *	2007-01-15	2008-07-24	Santen Pharmaceutical Co., Ltd.	Indole derivative having i.kappa.b kinase .beta. inhibitory activity
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
RU2499592C2 (ru)	2008-04-21	2013-11-27	Отономи, Инк.	Фармацевтическая композиция для лечения ушных заболеваний
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
KR20110031481A (ko) *	2008-07-14	2011-03-28	산텐 세이야꾸 가부시키가이샤	카르바모일기, 우레이드기 및 치환 옥시기를 갖는 신규 인돌 유도체
MD4009C2 (ro) *	2008-07-15	2010-08-31	Институт Химии Академии Наук Молдовы	Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
JP5312466B2 (ja)	2008-10-02	2013-10-09	旭化成ファーマ株式会社	８位置換イソキノリン誘導体及びその用途
DE102008052943A1 (de) *	2008-10-23	2010-04-29	Merck Patent Gmbh	Azaindolderivate
EP2351753B1 (en) *	2008-10-23	2015-02-11	Kabushiki Kaisha Yakult Honsha	PHENANTHROINDOLIZIDINE DERIVATIVE AND NF kB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20110305706A1 (en) *	2009-02-23	2011-12-15	Scott Thomas Brady	Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
WO2011023754A1 (en)	2009-08-26	2011-03-03	Sanofi-Aventis	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PH12013500256A1 (en)	2010-08-12	2013-03-18	Sanofi Sa	Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives
CN102584842A (zh) *	2011-01-17	2012-07-18	北京大学	取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6851965B2 (ja)	2014-09-26	2021-03-31	サハイバートナガールラジェンドラ	疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
EP3478269A4 (en)	2016-06-29	2020-04-08	Otonomy, Inc.	OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
SG11202005700SA (en) *	2017-12-19	2020-07-29	Bristol Myers Squibb Co	Amide substituted indole compounds useful as tlr inhibitors
US20210236398A1 (en) *	2020-01-31	2021-08-05	L'oreal	Compositions and methods for hair
FR3107832B1 (fr) *	2020-03-05	2022-04-29	Oreal	Compositions et procédés pour les cheveux

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU675680B2 (en) *	1992-10-14	1997-02-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
GB9225141D0 (en) *	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
JP3213426B2 (ja) *	1993-02-19	2001-10-02	エーザイ株式会社	６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
IT1271352B (it) *	1993-04-08	1997-05-27	Boehringer Ingelheim Italia	Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
GB9605065D0 (en) *	1996-03-11	1996-05-08	Merck Sharp & Dohme	Therapeutic agents
AU3767997A (en) *	1996-08-01	1998-02-25	Merckle Gmbh	Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
FR2751966B1 (fr) *	1996-08-01	1998-10-30	Union Pharma Scient Appl	Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
KR20000057137A (ko) *	1996-11-19	2000-09-15	스티븐 엠. 오드레	아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
NZ503491A (en) *	1997-11-10	2002-08-28	Bristol Myers Squibb Co	2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
CN1310706A (zh) *	1998-02-25	2001-08-29	遗传研究所有限公司	磷脂酶抑制剂
SK286857B6 (sk) *	1999-06-23	2009-06-05	Sanofi-Aventis Deutschland Gmbh	Substituované benzimidazoly, spôsob ich prípravy, ich použitie a liečivo, ktoré ich obsahuje
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
GT200500111A (es)	2004-05-12	2006-05-09		Acido 2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor de la cinasa ikb

1999
- 1999-10-26 DE DE19951360A patent/DE19951360A1/de not_active Withdrawn
2000
- 2000-10-17 AT AT00974405T patent/ATE437867T1/de active
- 2000-10-17 WO PCT/EP2000/010210 patent/WO2001030774A1/de not_active Ceased
- 2000-10-17 ME MEP-2008-655A patent/ME00434B/me unknown
- 2000-10-17 RS YUP-217/02A patent/RS50424B/sr unknown
- 2000-10-17 AU AU12728/01A patent/AU781553B2/en not_active Ceased
- 2000-10-17 NZ NZ518587A patent/NZ518587A/en not_active IP Right Cessation
- 2000-10-17 CA CA2389165A patent/CA2389165C/en not_active Expired - Fee Related
- 2000-10-17 IL IL14927200A patent/IL149272A0/xx active IP Right Grant
- 2000-10-17 CZ CZ2002-1413A patent/CZ304885B6/cs not_active IP Right Cessation
- 2000-10-17 DE DE50015700T patent/DE50015700D1/de not_active Expired - Lifetime
- 2000-10-17 SK SK543-2002A patent/SK287116B6/sk not_active IP Right Cessation
- 2000-10-17 ES ES00974405T patent/ES2329871T3/es not_active Expired - Lifetime
- 2000-10-17 BR BRPI0015026-6A patent/BR0015026B1/pt not_active IP Right Cessation
- 2000-10-17 RU RU2002113651/04A patent/RU2255087C2/ru not_active IP Right Cessation
- 2000-10-17 DK DK00974405T patent/DK1261601T3/da active
- 2000-10-17 KR KR1020027005395A patent/KR100795709B1/ko not_active Expired - Fee Related
- 2000-10-17 CN CNB008144729A patent/CN1172929C/zh not_active Expired - Fee Related
- 2000-10-17 SI SI200031041T patent/SI1261601T1/sl unknown
- 2000-10-17 HR HR20020357A patent/HRP20020357B1/xx not_active IP Right Cessation
- 2000-10-17 MX MXPA02003998A patent/MXPA02003998A/es active IP Right Grant
- 2000-10-17 PL PL354528A patent/PL200115B1/pl unknown
- 2000-10-17 PT PT00974405T patent/PT1261601E/pt unknown
- 2000-10-17 EE EEP200200217A patent/EE05036B1/et not_active IP Right Cessation
- 2000-10-17 EP EP00974405A patent/EP1261601B1/de not_active Expired - Lifetime
- 2000-10-17 HU HU0203228A patent/HU229215B1/hu not_active IP Right Cessation
- 2000-10-17 JP JP2001533128A patent/JP3843012B2/ja not_active Expired - Fee Related
- 2000-10-17 TR TR2002/01144T patent/TR200201144T2/xx unknown
2002
- 2002-04-17 NO NO20021808A patent/NO323952B1/no not_active IP Right Cessation
- 2002-04-22 IL IL149272A patent/IL149272A/en not_active IP Right Cessation
- 2002-04-23 ZA ZA200203204A patent/ZA200203204B/en unknown
- 2002-10-04 US US10/263,691 patent/US20030119820A1/en not_active Abandoned
2004
- 2004-05-11 US US10/842,427 patent/US20040209868A1/en not_active Abandoned
2005
- 2005-07-22 US US11/187,396 patent/US7342029B2/en not_active Expired - Fee Related
2009
- 2009-10-26 CY CY20091101115T patent/CY1110521T1/el unknown

Also Published As

Publication number	Publication date
CY1110521T1 (el)	2015-04-29
NO20021808L (no)	2002-04-17
DE19951360A1 (de)	2001-05-03
RU2255087C2 (ru)	2005-06-27
SK5432002A3 (en)	2002-11-06
ES2329871T3 (es)	2009-12-02
JP3843012B2 (ja)	2006-11-08
EP1261601B1 (de)	2009-07-29
AU781553B2 (en)	2005-05-26
CA2389165A1 (en)	2001-05-03
SK287116B6 (sk)	2009-12-07
WO2001030774A1 (de)	2001-05-03
EE05036B1 (et)	2008-06-16
HK1049671A1 (zh)	2003-05-23
US20050282866A1 (en)	2005-12-22
IL149272A (en)	2007-02-11
HU229215B1 (en)	2013-09-30
NZ518587A (en)	2004-06-25
KR20030004302A (ko)	2003-01-14
US20040209868A1 (en)	2004-10-21
PT1261601E (pt)	2009-10-15
SI1261601T1 (sl)	2009-12-31
CN1172929C (zh)	2004-10-27
YU21702A (sh)	2004-11-25
CZ304885B6 (cs)	2015-01-07
DK1261601T3 (da)	2009-11-16
NO20021808D0 (no)	2002-04-17
HUP0203228A3 (en)	2004-01-28
NO323952B1 (no)	2007-07-23
ATE437867T1 (de)	2009-08-15
BR0015026B1 (pt)	2011-11-29
CN1379772A (zh)	2002-11-13
KR100795709B1 (ko)	2008-01-21
ZA200203204B (en)	2002-10-23
PL200115B1 (pl)	2008-12-31
US20030119820A1 (en)	2003-06-26
AU1272801A (en)	2001-05-08
IL149272A0 (en)	2002-11-10
ME00434B (me)	2011-10-10
HRP20020357B1 (hr)	2010-10-31
TR200201144T2 (tr)	2003-02-21
HRP20020357A2 (en)	2004-02-29
DE50015700D1 (de)	2009-09-10
HUP0203228A2 (hu)	2003-02-28
CZ20021413A3 (cs)	2002-07-17
PL354528A1 (en)	2004-01-26
US7342029B2 (en)	2008-03-11
BR0015026A (pt)	2002-07-16
CA2389165C (en)	2010-11-16
EP1261601A1 (de)	2002-12-04
MXPA02003998A (es)	2002-10-23
RS50424B (sr)	2009-12-31
JP2003519101A (ja)	2003-06-17

Publication	Publication Date	Title
EE05036B1 (et)	2008-06-16	Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
DK1194425T3 (da)	2005-11-21	Substituerede benzimidazoler
PT933993E (pt)	2006-10-31	Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
IS1904B (is)	2003-11-20	Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
BR0309875A (pt)	2007-04-10	métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DK0751939T5 (da)	2004-11-08	Naphthylamider som centralnervesystemmidler
SG169224A1 (en)	2011-03-30	Method for treatment of tumors using nordihydrogualaretic acid derivatives
SE9900961D0 (sv)	1999-03-16	Novel compounds
ATE350030T1 (de)	2007-01-15	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
SE9802208D0 (sv)	1998-06-22	Novel compounds
ATE275400T1 (de)	2004-09-15	Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
WO2003063791A3 (en)	2003-12-31	Non-steroidal analogs of 2-methoxyestradiol
AU2284001A (en)	2001-07-09	Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
ATE286883T1 (de)	2005-01-15	Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
AU2002332488A1 (en)	2004-02-25	R-bambuterol, its preparation and therapeutic uses
SE9802209D0 (sv)	1998-06-22	Novel compounds
HK1045987A1 (zh)	2002-12-20	3-氨基-2-苄基-1-苯基-丙烷衍生物
ATE297926T1 (de)	2005-07-15	Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
BG105984A (bg)	2002-04-30	Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE286728T1 (de)	2005-01-15	Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen
SE9901079D0 (sv)	1999-03-23	Novel compounds
EA200501053A1 (ru)	2005-12-29	Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы

Legal Events

Date	Code	Title	Description
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2019-06-17	MM4A	Lapsed by not paying the annual fees	Effective date: 20181017